Multi-Institutional Paper Highlights the Destructive Benefits of Cryoablation

Article details how the combinatorial physical and molecular destruction caused by freezing is leading to a resurgence in the use of cryotherapy.

June 8, 2015

OWEGO, NY - CPSI Biotech announced today the publication of a peer-reviewed article detailing the combinatorial physical and molecular assault caused by the freezing process in tissues during cryoablation. The manuscript, titled Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue published in this month’s issue of Prostate Cancer and Prostatic Diseases (Issue 18; pages 87-95), was a multi-institutional collaboration between academic and corporate thought leaders in the field of cryoablation and included researchers from CPSI, the University of Minnesota and Binghamton University in conjunction with clinicians from Wake Forrest University School of Medicine, SUNY Buffalo School of Medicine and Duke University Medical Center.

The article details the current state of “re-purposing” cryoablation in cancer treatment due to its multi modal anticancer nature coupled with our ever evolving understanding of cancer biology, covering the topic from the investigational and clinical perspectives. Discussion includes a focus of the mechanisms of action of cryo, cancer biology, molecular–based therapeutic strategies and clinical outcomes for the cryoablation of prostate and renal cancers. Commenting on the article, Dr. John M. Baust (President and Lead Scientist, CPSI Biotech) stated “this review provides linkages between scientific research and clinical outcome yielding a path for understanding the clinically observed differences in patient response to cancer treatment, and by doing so, may provide insight to urologists to help further optimize the use of cryoablation.”

Discussing this article with the lead researcher on the collaboration, Dr. John G. Baust (Director of the Institute of Biomedical Technology and Lead Professor, Binghamton University) stated “this review, to our knowledge, represents the first integrative assessment of the linkage between cryoablation and the biology of the tumor environment, making the point that most all of the defensive strategies adopted by prostate and renal cancers are impacted. As a monotherapy, cryoablation functions as a single application therapy, in contrast with radiation and chemotherapy, thereby preventing the activation of diverse cancer defensive strategies. The article also discusses the benefits of cryoablation in destroying both the primary cancer cells as well as cancer stem cells, which are known to evade numerous anticancer therapies including radiation and chemotherapy.”

The article, initially published online in January, is timely in view of the recent increased interest in use of cryoablation for the treatment of cancer and can accesses via the Prostate Cancer and Prostatic Diseases website at http://www.nature.com/pcan/journal/v18/n2/full/pcan201454a.html
About CPSI Biotech - CPSI Biotech, a private, integrative bio/medtech greenhouse company, develops and designs life science research products and cryo-medical devices for applications in cancer, cardiovascular disease treatments and cell therapy bioprocessing. Ongoing R&D and business development activities continue to produce innovative technologies, devices and intellectual property for commercialization, licensing or sales in support of diverse clinical and research applications. By leveraging the innovation, flexibility and R&D strengths of CPSI in combination with the development, commercialization, manufacturing and clinical expertise of partnering organizations, rapid and efficient product development is attainable.

Disclosure Notice: The information contained in this release is as of June 2015. CPSI assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. CPSI’s technologies do not have regulatory clearance for commercial sale and are currently intended for “Research Use Only”.

With the exception of the historical information contained in this release, this release contains materials and statements related to future business, financial performance, future events and/or developments involving CPSI which constitute forward-looking statements. The matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to, CPSI’s ability to develop and market new products, to retain and attract key employees, to obtain regulatory clearances and approvals for its products, to effectively react to other risks and uncertainties, such as fluctuation of quarterly financial results, contract and grants acquisition, reliance on third party manufacturers and suppliers, litigation or other proceedings, economic, competitive, governmental impacts, whether pending patents will be granted or defendable, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, competition from existing and new products and procedures and CPSI’s ability to raise the capital that is required to accomplish the foregoing.

Contacts
CPSI Biotech Contact:
John M Baust, Ph.D., President & Lead Scientist
Kristi Snyder, Ph.D., Director of Operations
607-687-8701
contact@cpsibiotech.com